Moderna Statistics
Total Valuation
Moderna has a market cap or net worth of $39.05 billion. The enterprise value is $31.89 billion.
| Market Cap | 39.05B |
| Enterprise Value | 31.89B |
Important Dates
The next confirmed earnings date is Thursday, May 2, 2024, before market open.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Moderna has 382.88 million shares outstanding. The number of shares has decreased by -8.17% in one year.
| Shares Outstanding | 382.88M |
| Shares Change (YoY) | -8.17% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 9.62% |
| Owned by Institutions (%) | 73.18% |
| Float | 344.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.74 |
| Forward PS | 9.15 |
| PB Ratio | 2.84 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43, with a Debt / Equity ratio of 0.09.
| Current Ratio | 3.43 |
| Quick Ratio | 3.15 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.90% and return on invested capital (ROIC) is -28.13%.
| Return on Equity (ROE) | -29.90% |
| Return on Assets (ROA) | -22.50% |
| Return on Capital (ROIC) | -28.13% |
| Revenue Per Employee | $1.22M |
| Profits Per Employee | -$841,786 |
| Employee Count | 5,600 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 8.15 |
Taxes
In the past 12 months, Moderna has paid $772.00 million in taxes.
| Income Tax | 772.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.03% in the last 52 weeks. The beta is 1.59, so Moderna's price volatility has been higher than the market average.
| Beta (1Y) | 1.59 |
| 52-Week Price Change | -28.03% |
| 50-Day Moving Average | 100.33 |
| 200-Day Moving Average | 99.09 |
| Relative Strength Index (RSI) | 47.38 |
| Average Volume (30 Days) | 3,806,245 |
Short Selling Information
The latest short interest is 21.44 million, so 5.60% of the outstanding shares have been sold short.
| Short Interest | 21.44M |
| Short Previous Month | 22.23M |
| Short % of Shares Out | 5.60% |
| Short % of Float | 6.22% |
| Short Ratio (days to cover) | 5.26 |
Income Statement
In the last 12 months, Moderna had revenue of $6.85 billion and -$4.71 billion in losses. Loss per share was -$12.33.
| Revenue | 6.85B |
| Gross Profit | 2.16B |
| Operating Income | -4.24B |
| Pretax Income | -3.94B |
| Net Income | -4.71B |
| EBITDA | -3.32B |
| EBIT | -3.94B |
| Loss Per Share | -$12.33 |
Balance Sheet
The company has $8.60 billion in cash and $1.22 billion in debt, giving a net cash position of $7.39 billion or $19.29 per share.
| Cash & Cash Equivalents | 8.60B |
| Total Debt | 1.22B |
| Net Cash | 7.39B |
| Net Cash Per Share | $19.29 |
| Equity / Book Value | 13.85B |
| Book Value Per Share | 36.18 |
| Working Capital | 7.31B |
Cash Flow
In the last 12 months, operating cash flow was -$3.12 billion and capital expenditures -$707.00 million, giving a free cash flow of -$3.83 billion.
| Operating Cash Flow | -3.12B |
| Capital Expenditures | -707.00M |
| Free Cash Flow | -3.83B |
| FCF Per Share | -$10.01 |
Margins
Gross margin is 31.47%, with operating and profit margins of -61.90% and -68.84%.
| Gross Margin | 31.47% |
| Operating Margin | -61.90% |
| Pretax Margin | -57.56% |
| Profit Margin | -68.84% |
| EBITDA Margin | -48.50% |
| EBIT Margin | -57.56% |
| FCF Margin | -55.86% |
Dividends & Yields
Moderna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 8.17% |
| Shareholder Yield | 8.17% |
| Earnings Yield | -12.00% |
| FCF Yield | -9.74% |
Analyst Forecast
The average price target for Moderna is $132.00, which is 29.41% higher than the current price. The consensus rating is "Hold".
| Price Target | $132.00 |
| Price Target Difference | 29.41% |
| Analyst Consensus | Hold |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 19.87% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Moderna has an Altman Z-Score of 6.33 and a Piotroski F-Score of 3.
| Altman Z-Score | 6.33 |
| Piotroski F-Score | 3 |